A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

Фаза 3 Прекращено NCT06635135

Кратко

The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.

Time From Randomization Into Double Blind (DB) Treatment Maintenance Phase to the First Documentation of Relapse

From date of DB randomization (Day 113) up to first documentation of relapse (up to early termination of study [Day 140]) · days

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• CBT+ for Depression — University of Wisconsin, Madison
• Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
• Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
• Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
• A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
• Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital

Все исследования